EN DE
STOCK COMPARISON

Johnson & Johnson vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Johnson & Johnson (JNJ) and Eli Lilly and (LLY) compare, as of Aug 5, 2026.

As of Aug 5, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Johnson & Johnson trades at $255 versus a fair value of $169 (-34%), while Eli Lilly and trades at $1,116 versus $397 (-64%).
Johnson & Johnson
JNJ · USD · Health Care
-34%
upside to fair value
overvalued
Price$255
Fair Value$169
Quality84/100
Eli Lilly and
LLY · USD · Health Care
-64%
upside to fair value
overvalued
Price$1,116
Fair Value$397
Quality73/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Johnson & JohnsonEli Lilly and
Valuation
29.4×P/E (TTM)42.2×
6.34×P/S (TTM)14.67×
7.49×P/B39.94×
18.4×EV/EBITDA30.2×
4.95×PEG1.54×
2.0%Dividend yield0.5%
$5.20Dividend per share$6.23
Profitability
22%Net margin35%
27%Operating margin49%
26%Return on equity107%
8%Return on assets21%
Growth
10%Revenue growth (YoY)56%
5.6%Avg. growth/yr (3Y)31.7%
2.7%Avg. growth/yr (5Y)21.6%
Balance & size
0.48×Debt / equity1.54×
$611BMarket cap$1.1T
healthyGrowth qualitymixed

Eli Lilly and leads: 6 to 8 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Johnson & Johnsonof which business quality 76 · market factors 84 Eli Lilly andof which business quality 65 · market factors 75
ProfitabilityMargins and returns on capital today
74
85
Quality GrowthAre margins and returns improving?
73
86
CashflowEarnings quality: real cash, not paper profit
70
51
Fin. StrengthBalance sheet, leverage, solvency risk
72
53
InvestmentDisciplined investing over empire-building
87
15
Low VolatilityCalm price path (market factor)
96
74
MomentumPrice trend over the last 3–12 months (market factor)
71
72
52W MomentumDistance to the 52-week high (market factor)
91
83
Net IssuanceBuybacks instead of dilution
90
93

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Johnson & Johnson

DCF Models$161
Earnings-Based$73.34
Dividend Discount$93.41
Multiples$136
Asset-Based$22.70
Growth DCF$121
Economic Profit$102
Growth Earnings$190

26 of 26 models see the stock below the current price.

Eli Lilly and

DCF Models$323
Earnings-Based$239
Dividend Discount$115
Multiples$303
Asset-Based$19.94
Growth DCF$171
Economic Profit$347
Growth Earnings$353

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Johnson & Johnson
Bear $108Fair Value $169Bull $269
$255 = current price (white tick)
Eli Lilly and
Bear $222Fair Value $397Bull $582
$1,116 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Johnson & Johnson · Health Care

Quality score84 · Top 25%
Fair value upside-34% · below median

Eli Lilly and · Health Care

Quality score73 · Top 25%
Fair value upside-64% · bottom 25%

Bottom line

As of Aug 5, 2026, Fair Value Calculator sees Johnson & Johnson as the less overvalued of the two: Johnson & Johnson trades at $255 versus a fair value of $169 (-34%), while Eli Lilly and trades at $1,116 versus $397 (-64%).

Johnson & Johnson has the higher quality score (84/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.